EHA 2021 | The changing induction therapy landscape for myeloma
Elena Zamagni
• 23 Jun 2021
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, shares her views on when is best to initiate therapy upfront for the treatment of newly diagnosed multiple myeloma. Dr Zamagni highlights the potential role of novel biomarkers, and comments on potential changes to risk-stratification and treatment criteria in the future, as well as reporting on the addition of daratumumab to bortezomib and lenalidomide regimens. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Elena Zamagni, MD, PhD, has received honoraria and participated in advisory boards for Janssen, BMS, Takeda. Amgen, Oncopeptide, GSK and Sanofi.
